Cullinan Associates Inc. Acquires 11,399 Shares of Boston Scientific Corporation $BSX

Cullinan Associates Inc. raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 91.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,799 shares of the medical equipment provider’s stock after purchasing an additional 11,399 shares during the period. Cullinan Associates Inc.’s holdings in Boston Scientific were worth $1,493,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. FWL Investment Management LLC bought a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in shares of Boston Scientific during the 4th quarter valued at $29,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.7%

NYSE:BSX traded down $0.32 during mid-day trading on Friday, reaching $44.67. 12,037,584 shares of the company’s stock traded hands, compared to its average volume of 18,748,692. The company has a 50 day moving average price of $49.41 and a 200-day moving average price of $67.70. The firm has a market capitalization of $66.40 billion, a price-to-earnings ratio of 18.69, a PEG ratio of 0.86 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 12-month low of $42.25 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has initiated a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 9,800 shares of company stock worth $554,012 over the last quarter. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday. Bank of America lowered their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. BTIG Research reiterated a “buy” rating and set a $65.00 price target on shares of Boston Scientific in a research report on Tuesday, June 16th. Jefferies Financial Group decreased their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Finally, Needham & Company LLC lowered their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $81.32.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.